The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...

Biden’s decision underscored two key challenges with the current CFIUS process: the absence of a clear tiered framework to ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Aussies are set to spend a whopping $535m on Valentine’s Day gifts for their partners this year, according to market ...

We recently published a list of 10 Best Stocks To Buy For Financial Stability. In this article, we are going to take a look ...

Aussies are set to spend a whopping $535m on Valentine’s Day gifts for their partners this year, with men likely to spend more on gifts than women, according to market researchers Roy Morgan. It marks ...

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...